Sign in Subscribe
Drugs

A Small Step Towards Personalized Medicine for Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

Researchers from Hong Kong have made a breakthrough in the treatment of non-small cell lung cancer (NSCLC), a type of cancer that accounts for approximately 85% of all lung cancer cases. According to a report published in Discovery Medicine, the Iressa Pan-Asia Study (IPASS) has shown that patients with a specific genetic mutation, epidermal growth factor receptor (EGFR), respond better to a targeted therapy called gefitinib than to conventional chemotherapy. This finding has the potential to revolutionize the treatment of NSCLC, allowing for more personalized and effective care.

Key Takeaways:

  • The Iressa Pan-Asia Study (IPASS) was a randomized phase III study that compared the effectiveness of gefitinib (EGFR tyrosine kinase inhibitor) with paclitaxel/carboplatin (standard chemotherapy) in Asian non-/light smokers with adenocarcinoma.
  • Progression-free survival (PFS) in EGFR mutation-positive patients was longer with gefitinib than with chemotherapy, with a hazard ratio of 0.48 and 95% confidence interval of 0.36-0.64.
  • The study's findings demonstrated that the EGFR mutation is a potent biomarker for lung cancer, predicting tumor response to and prolonged duration of disease control by EGFR tyrosine kinase inhibitors (TKI).
  • The study's results were published in Discovery Medicine and represent a small step towards personalized medicine for non-small cell lung cancer.

Statistics:

  • Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases.
  • The Iressa Pan-Asia Study (IPASS) was a randomized phase III study.
  • Progression-free survival (PFS) in EGFR mutation-positive patients was longer with gefitinib than with chemotherapy (hazard ratio HR, 0.48; 95% confidence interval CI, 0.36-0.64).
  • The study's findings demonstrate the potential for personalized medicine in the treatment of non-small cell lung cancer.

Sources:

  • Mok et al. (2009). A small step towards personalized medicine for non-small cell lung cancer. Discovery Medicine, 8(43), 227-231.

Read more